Bulk Manufacturer of Controlled Substances Application: Nalas Engineering Services, Inc., 34655-34656 [2020-12175]
Download as PDF
<![CDATA[
34655
Federal Register / Vol. 85, No. 109 / Friday, June 5, 2020 / Notices
Controlled substance
Drug code
Lisdexamfetamine ............................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Nabilone ...........................................................................................................................................................................
1-Phenylcyclohexylamine ................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Anileridine ........................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Etorphine HCl ..................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Isomethadone ..................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Meperidine intermediate-A ..............................................................................................................................................
Meperidine intermediate-B ..............................................................................................................................................
Meperidine intermediate-C ..............................................................................................................................................
Metazocine ......................................................................................................................................................................
Methadone .......................................................................................................................................................................
Methadone intermediate ..................................................................................................................................................
Metopon ...........................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Dihydroetorphine .............................................................................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Phenazocine ....................................................................................................................................................................
Thiafentanil ......................................................................................................................................................................
Piminodine .......................................................................................................................................................................
Racemethorphan .............................................................................................................................................................
Racemorphan ..................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
Bezitramide ......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
Moramide-intermediate ....................................................................................................................................................
lotter on DSK9F5VC42PROD with NOTICES
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
[FR Doc. 2020–12177 Filed 6–4–20; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: Nalas
Engineering Services, Inc.
ACTION:
VerDate Sep<11>2014
18:21 Jun 04, 2020
Jkt 250001
PO 00000
Notice of application.
Frm 00067
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 4, 2020.
DATES:
DEPARTMENT OF JUSTICE
[Docket No. DEA–657]
William T. McDermott,
Assistant Administrator.
1205
1631
1724
2125
2270
2315
2550
7379
7460
7471
8333
8501
8603
9010
9020
9041
9050
9059
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9240
9250
9254
9260
9273
9300
9330
9333
9334
9648
9652
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9801
9802
Schedule
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
E:\FR\FM\05JNN1.SGM
05JNN1
34656
Federal Register / Vol. 85, No. 109 / Friday, June 5, 2020 / Notices
In
accordance with 21 CFR 1301.33(a), this
is notice that on May 22, 2020, Nalas
Engineering Services, Inc., 85
Westbrook Road, Centerbrook,
Connecticut 06409, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance:
SUPPLEMENTARY INFORMATION:
Controlled
substance
Drug
code
Schedule
Thebaine .................
9333
II
The company plans to manufacture
derivatives of the above controlled
substance for distribution to its
customers.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–12175 Filed 6–4–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJJDP) Docket No. 1777]
Meeting of the Coordinating Council
on Juvenile Justice and Delinquency
Prevention
Coordinating Council on
Juvenile Justice and Delinquency
Prevention.
ACTION: Notice of meeting.
AGENCY:
The Coordinating Council on
Juvenile Justice and Delinquency
Prevention announces its next meeting.
DATES: Wednesday July 8th, 2020 at
10:00 a.m. ET.
ADDRESSES: The meeting will take place
in the third floor main conference room
at the U.S. Department of Justice, Office
of Justice Programs, 810 7th St. NW,
Washington, DC 20531.
FOR FURTHER INFORMATION CONTACT: Visit
the website for the Coordinating Council
at www.juvenilecouncil.gov or or contact
Elizabeth Wolfe, Designated Federal
Official (DFO), OJJDP, by telephone at
(202) 598–9310, email at
elizabeth.wolfe@ojp.usdoj.gov; or
Melissa Kanaya, Project Manager/
Federal Contractor, by telephone (202)
280–8874, email at Melissa.kanaya@
bixal.com, or fax at (866) 854–6619.
Please note that the above phone/fax
numbers are not toll free.
SUPPLEMENTARY INFORMATION: The
Coordinating Council on Juvenile
Justice and Delinquency Prevention
(‘‘Council’’), established by statute in
the Juvenile and Delinquency
Prevention Act of 1974 section 206(a)
lotter on DSK9F5VC42PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:21 Jun 04, 2020
Jkt 250001
(42 U.S.C. 5616(a)), will meet to carry
out its advisory functions. Information
regarding this meeting will be available
on the Council’s web page at
www.juvenilecouncil.gov. The meeting
is open to the public, and available via
online video conference, but prior
registration is required (see below). In
addition, meeting documents will be
viewable via this website including
meeting announcements, agendas,
minutes and reports.
Although designated agency
representatives may attend in lieu of
members, the Council’s formal
membership consists of the following
secretaries and/or agency officials;
Attorney General (Chair), Administrator
of the Office of Juvenile Justice and
Delinquency Prevention (Vice Chair),
Secretary of Health and Human Services
(HHS), Secretary of Labor (DOL),
Secretary of Education (DOE), Secretary
of Housing and Urban Development
(HUD), Director of the Office of National
Drug Control Policy, Chief Executive
Officer of the Corporation for National
and Community Service and the
Assistant Secretary of Homeland
Security for the U.S. Immigration and
Customs Enforcement. Nine additional
members are appointed by the Speaker
of the U.S. House of Representatives, the
U.S. Senate Majority Leader and the
President of the United States. Further
agencies that take part in Council
activities include, the Departments of
Agriculture, Defense, Interior and the
Substance and Mental Health Services
Administration of HHS.
Council meeting agendas are available
on www.juvenilecouncil.gov. Agendas
will generally include: (a) Opening
remarks and introductions; (b)
Presentations and discussion of agency
work; and (c) Council member
announcements.
For security purposes and because
space is limited, members of the public
who wish to attend must register in
advance of the meeting online at the
meeting registration site, no later than
Thursday, July 2, 2020. Should issues
arise with online registration, or to
register by fax or email, the public
should contact Melissa Kanaya, Project
Manager/Federal Contractor (see above
for contact information). If submitting
registrations via fax or email, attendees
should include all of the following:
Name, Title, Organization/Affiliation,
Full Address, Phone Number, Fax and
Email. The meeting will also be
available to join online via Webex, a
video conferencing platform.
Registration for this is also found online
at www.juvenilecouncil.gov.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
Note: Photo identification will be
required to attend the meeting at the
OJP 810 7th Street Building.
Interested parties may submit written
comments and questions in advance to
Elizabeth Wolfe (DFO) for the Council,
at the contact information above. If
faxing, please follow up with Melissa
Kanaya, Project Manager/Federal
Contractor (contact information above)
in order to assure receipt of
submissions. All comments and
questions should be submitted no later
than 5:00 p.m. ET on Thursday July
2nd, 2020.
The Council will limit public
statements if they are found to be
duplicative. Written questions
submitted by the public while in
attendance will also be considered by
the Council.
Elizabeth Wolfe,
Training and Outreach Coordinator, Office
of Juvenile Justice and Delinquency
Prevention.
[FR Doc. 2020–12138 Filed 6–4–20; 8:45 am]
BILLING CODE 4410–18–P
DEPARTMENT OF LABOR
Bureau of Labor Statistics
Proposed Collection; Comment
Request
Bureau of Labor Statistics,
Department of Labor.
ACTION: Notice of information collection;
request for comment.
AGENCY:
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and Federal agencies with an
opportunity to comment on proposed
and/or continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995. This
program helps to ensure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. The Bureau of Labor
Statistics (BLS) is soliciting comments
concerning the proposed extension
without change of a currently approved
collection for the ‘‘Producer Price
Index’’ survey. A copy of the proposed
information collection request (ICR) can
be obtained by contacting the individual
listed below in the Addresses section of
this notice.
SUMMARY:
E:\FR\FM\05JNN1.SGM
05JNN1
]]>Agencies
[Federal Register Volume 85, Number 109 (Friday, June 5, 2020)]
[Notices]
[Pages 34655-34656]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12175]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-657]
Bulk Manufacturer of Controlled Substances Application: Nalas
Engineering Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 4, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
[[Page 34656]]
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on May 22, 2020, Nalas Engineering Services, Inc., 85
Westbrook Road, Centerbrook, Connecticut 06409, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Thebaine............................. 9333 II
------------------------------------------------------------------------
The company plans to manufacture derivatives of the above
controlled substance for distribution to its customers.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-12175 Filed 6-4-20; 8:45 am]
BILLING CODE 4410-09-P
